Open Access

Panel discussion - Expanding current insights of non-vitamin K antagonist oral anticoagulants in atrial fibrillation: clinical implications.

logo

Congress Presentation

About the speakers

Doctor Jeffrey Weitz

Thrombosis & Atherosclerosis Research Institute (TaARI), Hamilton (Canada)
25 presentations
1 follower

Professor Gregory Yh Lip

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)
90 presentations
9 followers

Doctor Robert Giugliano

Brigham and Women's Hospital, Boston (United States of America)
13 presentations
1 follower

Professor Andreas Goette

Saint Vincenz Hospital Paderborn, Paderborn (Germany)
37 presentations
0 follower

Professor Hein Heidbuchel

University Hospital Antwerp, Antwerp (Belgium)
55 presentations
5 followers

5 more presentations in this session

Welcome and introduction - Expanding current insights of non-vitamin K antagonist oral anticoagulants in atrial fibrillation: clinical implications.

Speaker: Doctor J. Weitz (Hamilton, CA)

Thumbnail

Non-vitamin K antagonist oral anticoagulants in cardioversion: the ENSURE-AF study.

Speaker: Professor A. Goette (Paderborn, DE)

Thumbnail

Update from ENGAGE AF-TIMI 48: clinical implications.

Speaker: Doctor R. Giugliano (Boston, US)

Thumbnail

Management of atrial fibrillation: the new European Society of Cardiology 2016 Guidelines.

Speaker: Professor H. Heidbuchel (Antwerp, BE)

Thumbnail

Summary and key messages - Expanding current insights of non-vitamin K antagonist oral anticoagulants in atrial fibrillation: clinical implications.

Speaker: Professor G. Lip (Liverpool, GB)

Thumbnail

Access the full session

Expanding current insights of non-vitamin K antagonist oral anticoagulants in atrial fibrillation: clinical implications

Speakers: Doctor J. Weitz, Professor G. Lip, Doctor R. Giugliano, Professor A. Goette, Professor H. Heidbuchel...
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb